Phenotype
|
Conditions
|
Figures
|
apoptotic process increased occurrence, abnormal
|
control
|
Fig. 2
from Kim et al., 2019
|
apoptotic process increased occurrence, exacerbated
|
chemical treatment by environment: tert-butyl hydroperoxide
|
Fig. 2
from Kim et al., 2019
|
apoptotic process occurrence, ameliorated
|
chemical treatment by environment: N-acetyl-L-cysteine, chemical treatment by environment: tert-butyl hydroperoxide
|
Fig. 2
from Kim et al., 2019
|
inflammatory response increased process quality, abnormal
|
standard conditions
|
Fig. 3
from Kim et al., 2019
|
intestine atrophied, abnormal
|
standard conditions
|
Fig. 4
from Kim et al., 2019
|
intestine tnfa expression increased amount, abnormal
|
standard conditions
|
Fig. 5
from Kim et al., 2019
|
intestine rela expression increased amount, abnormal
|
standard conditions
|
Fig. 5
from Kim et al., 2019
|
intestine mpx expression increased amount, abnormal
|
standard conditions
|
Fig. 5
from Kim et al., 2019
|
intestine inflamed, abnormal
|
standard conditions
|
Fig. 4
from Kim et al., 2019
|
intestine apoptotic process increased occurrence, abnormal
|
standard conditions
|
Fig. 5
from Kim et al., 2019
|
intestine inflammatory response increased occurrence, abnormal
|
standard conditions
|
Fig. 4 ,
Fig. 5
from Kim et al., 2019
|
pancreas inflamed, abnormal
|
standard conditions
|
Fig. 4
from Kim et al., 2019
|
pancreas inflammatory response increased occurrence, abnormal
|
standard conditions
|
Fig. 4
from Kim et al., 2019
|
reactive oxygen species biosynthetic process increased occurrence, abnormal
|
control
|
Fig. 2
from Kim et al., 2019
|
reactive oxygen species biosynthetic process increased occurrence, exacerbated
|
chemical treatment by environment: tert-butyl hydroperoxide
|
Fig. 2
from Kim et al., 2019
|
reactive oxygen species biosynthetic process occurrence, ameliorated
|
chemical treatment by environment: N-acetyl-L-cysteine, chemical treatment by environment: tert-butyl hydroperoxide
|
Fig. 2
from Kim et al., 2019
|
spleen inflamed, abnormal
|
standard conditions
|
Fig. 4
from Kim et al., 2019
|
spleen inflammatory response increased occurrence, abnormal
|
standard conditions
|
Fig. 4
from Kim et al., 2019
|
whole organism sirt1 expression absent, abnormal
|
standard conditions
|
Fig. 1
from Kim et al., 2019
|
whole organism decreased life span, abnormal
|
standard conditions
|
Fig. 5
from Kim et al., 2019
|
whole organism socs3a expression increased amount, abnormal
|
standard conditions
|
Fig. 3
from Kim et al., 2019
|
whole organism il6 expression increased amount, abnormal
|
standard conditions
|
Fig. 3
from Kim et al., 2019
|
whole organism socs1a expression increased amount, abnormal
|
standard conditions
|
Fig. 3
from Kim et al., 2019
|
whole organism nfe2l2a expression increased amount, abnormal
|
standard conditions
|
Fig. 3
from Kim et al., 2019
|
whole organism il1b expression increased amount, abnormal
|
standard conditions
|
Fig. 3
from Kim et al., 2019
|
whole organism nos2a expression increased amount, abnormal
|
standard conditions
|
Fig. 3
from Kim et al., 2019
|
whole organism casp3a expression increased amount, abnormal
|
standard conditions
|
Fig. 3
from Kim et al., 2019
|
whole organism tnfa expression increased amount, abnormal
|
standard conditions
|
Fig. 3
from Kim et al., 2019
|
whole organism tgfb1a expression increased amount, abnormal
|
standard conditions
|
Fig. 3
from Kim et al., 2019
|
whole organism viability, ameliorated
|
chemical treatment by environment: tert-butyl hydroperoxide
|
Fig. 2
from Kim et al., 2019
|